WebWith Harbr, you can quickly and easily scan documents and extract text, saving you valuable time and effort. No more sifting through piles of paperwork or countless digital … WebBackground: The optimal duration of antiplatelet therapy in high-bleeding risk (HBR) patients with coronary artery disease treated with newer-generation drug-eluting bioresorbable …
Clopidogrel versus ticagrelor in high-bleeding risk patients
Web11 apr 2024 · For example, in the LEADERS FREE trial, despite a recommended 1-month DAPT duration, ≈9% remained on DAPT after 1 month. 4 In the SENIOR trial, 20% of patients remained on DAPT at 12 months, well beyond the recommended 1 to 6 months. 6 In the ZEUS trial, although all patients at HBR were prescribed DAPT for 30 days, 38% … WebBackground: The optimal duration of antiplatelet therapy in high-bleeding risk (HBR) patients with coronary artery disease treated with newer-generation drug-eluting bioresorbable polymer-coated stents remains unclear. Design: MASTER DAPT (clinicaltrial.govNCT03023020) is an investigator-initiated, open-label, multicenter, … shortness of breath sickness
Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT
WebLa durata ottimale della doppia terapia antipiastrinica (DAPT) dopo intervento coronarico percutaneo (PCI) nei pazienti ad alto rischio di sanguinamento (HBR) è ancora dibattuta. È stata pubblicata recentemente una metanalisi che ha valutato l'impatto di un regime DAPT abbreviato nei pazienti con HBR. È stata eseguita una revisione ... Web17 mag 2024 · Complex HBR patients had the most to gain from longer DAPT, but even here, the shorter regimen seemed to hold up. PARIS, France—One month of dual antiplatelet therapy (DAPT), compared with 3 months or longer, is sufficient for PCI patients at high bleeding risk (HBR) regardless of procedural complexity, according to a … Web26 ago 2024 · A. A. A. In patients at high risk for bleeding, discontinuation of dual antiplatelet therapy (DAPT) at one month after implantation of a biodegradable-polymer sirolimus-eluting coronary stent was noninferior to the standard therapy in terms of net adverse clinical events and major adverse cardiac or cerebral events, according to findings from ... shortness of breath stomach discomfort